Rosa Gomes Alves Martins,Mehmet M Tekin,Mark S Cragg et al.
Rosa Gomes Alves Martins et al.
Tumour-associated macrophages (TAM) are present in the majority of tumours, where they comprise one of the most abundant cell types, influencing tumour progression, metastasis, therapy resistance, and relapse. Hence, there is a great intere...
Intra-tumoural RAMP1+ B cells promote resistance to neoadjuvant anti-PD-1-based therapy in oesophageal squamous cell carcinoma [0.03%]
肿瘤内RAMP1+B细胞促进食管鳞状细胞癌对新辅助抗PD-1治疗的耐药性
Hongyu Zhang,Yuchen Zhang,Pingjing Zhou et al.
Hongyu Zhang et al.
Introduction: The application of neoadjuvant immunotherapy in oesophageal squamous cell carcinoma (ESCC) reactivates anti-tumour immune responses and prolong postoperative survival. However, due to the heterogeneity of tu...
Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small-cell lung cancer in UK clinical practice-Are the PACIFIC trial outcomes achievable in the real world? [0.03%]
在英国临床实践中III期非小细胞肺癌患者根治性同步放化疗后接受巩固免疫治疗的现状——PACIFIC研究结果可以在真实世界中实现吗？
Radwa Fawzy Ahmed,Paul Fenton,Adityanarayan Bhatnagar et al.
Radwa Fawzy Ahmed et al.
Introduction: PACIFIC trial demonstrates improved progression-free survival (PFS) and overall survival (OS) in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with platinum-based concurrent chemo...
Lag3 and PD-1 pathways preferentially regulate NFAT-dependent TCR signalling programmes during early CD4+ T cell activation [0.03%]
LAG3和PD-1途径在早期活化CD4+T细胞过程中选择性调节NFAT依赖型TCR信号转导程序
Lozan Sheriff,Alastair Copland,David A J Lecky et al.
Lozan Sheriff et al.
Introduction: Lag3 and PD-1 are immune checkpoints that regulate T cell responses and are current immunotherapy targets. Yet how they function to control early stages of CD4+ T cell activation remains unclear. ...
Harnessing monocyte dynamics for treatment of multiple sclerosis; insights from experimental model studies [0.03%]
借鉴实验模型研究揭示MS治疗新策略：调控单核细胞动态或许能治疗多发性硬化症
Aqsa Bibi,Zhenjiang Yu,Lv Cui et al.
Aqsa Bibi et al.
Monocytes are central to the innate immune system's response to infection or injury. In murine, these cells are classified into distinct subsets: classical monocytes, defined by elevated Ly6C expression (Ly6Chi), intermediate monocytes (Ly6...
M2 macrophages promote IL-10+B-cell production and alleviate asthma in mice [0.03%]
M2型巨噬细胞促进IL-10+B细胞的生成并缓解小鼠哮喘症状
Baichao Yu,Xueqi Wang,Yongkun Zheng et al.
Baichao Yu et al.
Introduction: B cells have a central regulatory role in various diseases. While macrophages are found in the disease microenvironment and interact with tissue and diverse immune cells, their relationship with B cells rema...
Abnormal glucose and lipid metabolism promotes disrupted differentiation of T and B cell subsets in Behçet's disease [0.03%]
糖脂代谢紊乱影响贝赫切特病患者T/B淋巴细胞分化异常
Minghao Li,Ping Li,Xin Wang et al.
Minghao Li et al.
Introduction: Behçet's disease (BD) is a chronic, systemic inflammatory condition characterized by recurrent immune dysregulation. Materials & methods: ...
Development and evaluation of two whole-blood flow cytometry protocols for monitoring patients treated with JAK inhibitors [0.03%]
两种用于监测接受JAK抑制剂治疗患者的全血流式细胞术方案的开发和评估
Louis Waeckel,Chloé Talon,Mathilde Barrau et al.
Louis Waeckel et al.
Introduction: The clinical efficacy of Janus kinase inhibitors (JAKinibs) is highly variable and their safety profiles are poorly understood. Methods: ...
Human challenge models for vaccine development-strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report [0.03%]
人用疫苗开发挑战模型会议报告：成就、局限及在地方病流行地区的发展展望
Helen R Wagstaffe,Stephanie Ascough,Peter J M Openshaw;HIC-Vac meeting contributors
Helen R Wagstaffe
The HIC-Vac network is a unique association of researchers focussed on the development and use of human infection challenge (HIC, otherwise known as controlled human infection models or CHIM) studies for vaccine and therapeutic development,...
Frank J Ward,Paul T Kennedy,Farah Al-Fatyan et al.
Frank J Ward et al.
Immune checkpoint inhibitor (ICI) therapies have revolutionized cancer therapy and improved patient outcomes in a range of cancers. ICIs enhance anti-tumour immunity by targeting the inhibitory checkpoint receptors CTLA-4, PD-1, PD-L1, and ...